Related references
Note: Only part of the references are listed.Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
Mark C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Mark C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial
M. C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2013)
Long-term safety of abatacept in patients with rheumatoid arthritis
Fabiola Atzeni et al.
AUTOIMMUNITY REVIEWS (2013)
Belimumab - an anti-BLyS human monoclonal antibody for rheumatoid arthritis
Xingzhong Jin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study
Peter Nash et al.
ARTHRITIS CARE & RESEARCH (2013)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2010)
Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis
C. Bracewell et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Share Paper
